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Abstract
The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) was founded on 10 December 2009 with the initiative of
Roland Hetzer (Deutsches Herzzentrum Berlin, Berlin, Germany) and Jan Gummert (Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad
Oeynhausen, Germany) with 15 other founding international members. It aims to promote scientiﬁc research to improve care of end-stage
heart failure patients with ventricular assist device or a total artiﬁcial heart as long-termmechanical circulatory support. Likewise, the organization
aims to provide and maintain a registry of device implantation data and long-term follow-up of patients with mechanical circulatory support.
Hence, EUROMACS afﬁliated itself with Dendrite Clinical Systems Ltd to offer its members a software tool that allows input and analysis of
patient clinical data on a daily basis. EUROMACS facilitates further scientiﬁc studies by offering research groups access to any available data
wherein patients and centres are anonymized. Furthermore, EUROMACS aims to stimulate cooperation with clinical and research institutions
and with peer associations involved to further its aims. EUROMACS is the only European-based Registry for Patients with Mechanical Circulatory
Support with rapid increase in institutional and individual membership. Because of the expeditious data input, the European Association for
Cardiothoracic Surgeons saw the need to optimize the data availability and the signiﬁcance of the registry to improve care of patients with mech-
anical circulatory support and its potential contribution to scientiﬁc intents; hence, the beginning of their alliance in 2012. This ﬁrst annual report
is designed to provide an overview of EUROMACS’ structure, its activities, a ﬁrst data collection and an insight to its scientiﬁc contributions.
Keywords: End-stage heart failure • Registry • Mechanical circulatory support • Left ventricular assist device • Right ventricular assist device •
Biventricular assist device • Total artiﬁcial heart • Bridge to transplant
HISTORY AND BACKGROUND
The increasing routine use of ventricular assist devices (VADs) to keep
patients alive until heart transplantation paved the way to their clinical
use as an established treatment for end-stage heart failure by them-
selves. This has become essential in the face of the increasing organ
shortage. Moreover, the use of VADs also has increasing relevance as
the possible bridge to transplant (bridge to candidacy), such as in
the setting of pulmonary hypertension or curable neoplasia having
a follow-up of at least 5 years after successful treatment [1, 2] and
tumour-free for at least 1 year in highly selected cases [3].
These issues and the lack of a European registry have prompted
the creation of EUROMACS (European Registry for Patients with
Mechanical Circulatory Support e.V.) (e.V., German abbreviation
meaning ‘eingetragener Verein’: registered association, formally
registered at the Berlin Charlottenburg Court), by 15 international
members, registered in Berlin on 10 December 2009. Initial funds
were provided by the Friede-Springer-Herz-Stiftung and support
from various manufacturers (CircuLite, Inc., HeartWare, Inc., Micro-
Med, Syncardia Systems, Inc., Thoratec Corporation). Promotion
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of scientiﬁc research to improve care of end-stage heart failure
patients with VADs or a total artiﬁcial heart (TAH) as long-term
mechanical circulatory support (MCS) is its primary objective. In
2010, EUROMACS afﬁliated itself with Dendrite Clinical Systems
Ltd, a specialist supplier of clinical database and analysis, to offer
its members a secure software tool for the input and analysis of
patients’ clinical data on a daily basis. From then on, the database
was developed, and the registry became accessible in April 2012.
The contributing centres were advised to submit their data retro-
spectively as of 1 January 2011. The registry facilitates further sci-
entiﬁc studies by offering research groups access to anonymized
data. EUROMACS is the only existing European-based MCS regis-
try for all devices implanted in children and adults, which is in
contrary to other registries such as INTERMACS, which registers
only Food and Drug Administration (FDA)-approved devices and
no paediatric patients.
In 2012, EUROMACS became an ofﬁcial committee of the
European Association for Cardiothoracic Surgery (EACTS), and
hereby fulﬁls all by-laws of the association. The EACTS has taken
over the costs of EUROMACS. Likewise, EUROMACS afﬁliates with
the policies and quality programme of the EACTS.
This ﬁrst annual report aims to provide an overview of
EUROMACS’ activities, a ﬁrst data collection of the EUROMACS
registry and an insight to its scientiﬁc contributions.
STRUCTURE OF EUROMACS
In 2013, the legally registered constitution of EUROMACS ofﬁcially
declared itself as a Committee of the EACTS.
Figure 1 shows the organizational structure of EUROMACS. It
functions as an EACTS Committee, and as such, it follows the
EACTS policies and regulations. This allows any EACTS member to
join EUROMACS freely.
DATABASE DESIGN AND FUNCTION
The EUROMACS database has been designed in such a way that
the patient and device outcomes will be comparable with that
of the INTERMACS database. The software, developed by Dendrite
Clinical Systems Ltd is user-friendly, and can be accessed by either
MS Windows or Apple OS. It was made possible that security of
data according to German and European legislation is assured.
The centres can enter their data any time, using a unique pass-
word, and for safety reasons by using hypertext transfer protocol
secure (https) communication.
The database consists of two major parts, as follows:
(i) Implant data
(a) Basic patient data.
(b) Examinations and assessment prior to implant (e.g.
echocardiogram, haemodynamics, laboratory values and
medications).
(c) Surgical procedures.
(d) Clinical investigations and status at discharge.
(ii) Follow-up data
(a) Routine follow-up, e.g. out-patient visits.
(b) Events (major/minor bleeding, thromboembolism, infec-
tion, pump failure and/or exchange, problems with the
driveline, controller or the batteries, weaning, myocardial
recovery, transplantation, death).
Requirements for site participation and working area
Any hospital/centre/institution, contributing to EUROMACS is of-
fered a contract between their local institution and EUROMACS.
The agreement regulates that patients are informed according to
the national or local regulations. Furthermore, hospitals agree
to the complete and timely data entry of all patients who consent
to participate. In return, EUROMACS agrees to keep the data secured
and conﬁdential for other centres, provides data availability for clinic-
al analysis and addresses quality control.
The working area of EUROMACS is in those countries, which are
either entirely or partially located on the European continent.
However, if any centre outside this working area decides to par-
ticipate voluntarily in EUROMACS, such a centre would be free to
join the registry.
Since one of the primary objectives of EUROMACS is to promote
scientiﬁc research to improve care of end-stage heart failure patients
with long-term MCS, any centre or scientist who wants to use avail-
able data in the database, research proposals must be submitted to
the Executive Board. If for some reasons that the proposal is ren-
dered unsuitable, it is referred to the scientiﬁc advisory committee
for further assessment. All approved research proposals are moni-
tored to ensure that the data are used appropriately. In July 2013,
the ﬁrst scientiﬁc proposal to use EUROMACS data was granted;
hence, data were made available for analysis and publication [4].
Patient selection
All patients (adults and children) who receive long-term MCS are
eligible for registration in the EUROMACS database. However, a
provision has been made to register devices used for temporary
or short-term (≤30 days) support, which are implanted concomi-
tantly (as a temporary RVAD) with a long-term device and which
are designed to function for ≥6 months (Table 1).
Statistical analyses
Categorical variables are reported as number and percentage of
observations. Continuous variables are expressed as mean, median
and range. We generated Kaplan–Meier estimates to investigateFigure 1: The EUROMACS organizational structure.
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the probability of survival or event-free survival as a function of
time after VAD implantation. Results are presented for adults with
primary LVAD or BiVAD implants, and indicate mean values with
95% conﬁdence intervals. Patients were censored at the time of
transplantation, weaning or second VAD implantation.
APPROVED DEVICES
Table 1 lists the current devices with a European conformity (CE)
mark, which are approved for clinical use.
STATUS OF EUROMACS DATABASE
As previously mentioned, EUROMACS aims to create and operate a
European registry to assemble baseline and follow-up data of
patients receiving long-term MCS for the treatment of advanced
heart failure, to determine the factors inﬂuencing the clinical results.
Table 2 shows the 12 participating countries and 21 hospitals
contributing data to the EUROMACS database as of 31 December
2013. During the same date, the content of the contract with
EUROMACS was still being evaluated by the legal advisers in 27
centres (in 6 additional countries), for conformation with their
local or national regulatory requirements.
Participating hospitals register the implant data of newly enlisted
patients who consent to their enrolment in the EUROMACS data-
base. Follow-up data that include routine examinations and occur-
rence of events, are likewise registered. Provisions are made to
register patients with MCS from 1 January 2011 retrospectively.
Between 1 January 2011 and 31 December 2013, 741 patients
(mean age: 53.3, median: 56, range: 0–83 years) were registered in
the EUROMACS database. Most patients are Caucasians (n = 672,
90.7%) and males (n = 610, 82.3%). The aetiology of end-stage
heart failure was mostly idiopathic dilated cardiomyopathy (n =
348, 47%) and ischaemic cardiomyopathy (n = 294, 39.7%)
(Table 3). The distribution by AB0 blood group type is given in
Table 4. These data are deemed important for comparison with
the patients on organ transplant waiting lists.
Table 5 shows the types of VADs implanted stratiﬁed according
to age in the 713 patients of whom exact data were available.
Table 6 details primary and subsequently implanted devices
(n = 825) in 741 patients. An isolated LVAD was implanted in 636
(85.8%) patients. LVAD with a temporary RVAD was implanted in
45 (6.1%) patients. Isolated RVADs were implanted in 53 (7.1%),
and TAH in 9 (1.2%). Additionally, Table 6 shows that, after the ﬁrst
implantation of MCS, 70 patients underwent a second device
Table 1: Present CE marked MCS systems registered in
the EUROMACS database
MCS type Device
Long-term devices
Continuous flow Berlin Heart Incor
Circulite Synergy
Heart Assist 5
HeartWare HVAD
Jarvik 2000
MicroMed DeBakey
Thoratec HeartMate II
Pulsatile extracorporeal Berlin Heart Excor
Thoratec pVAD
Total artificial heart SynCardia Cardiowest
Short-term devices Abiomed AB5000
Deltastream Medos
Levitronix Centrimag
Maquet CardioHelp
CE: European conformity; MCS: mechanical circulatory support.
Table 2: Participating countries/institutions as of 31
December 2013
Country City, hospital
Belarus Minsk, Republican Scientific Practical Center
‘Cardiology’
Belgium Aalst, Onze Lieve Vrouwen Ziekenhuis
Gent, Academisch Ziekenhuis Gent
Czech Republic Prague, Institute for Clinical and Experimental
Medicine (IKEM)
Brno, Center for Cardiovascular and Transplant
Surgery
Denmark Copenhagen, Rigshospitalet
Germany Bad Oeynhausen, Herz- und Diabeteszentrum
Nordrhein-Westfalen
Berlin, Deutsches Herzzentrum Berlin (DHZB)
Freiburg, Universitäts-Herzzentrum Freiburg – Bad
Krozingen
Hamburg, Universitäres Herzzentrum Hamburg
Greece Thessaloniki, AHEPA University Hospital
Hungary Budapest, Heart Center of the Semmelweis
University
Budapest, Gottsegen Hungarian Institute of
Cardiology
Italy Bologna, San Orsola Hospital
Milan, Niguarda Ca Granda Hospital
Rome, San Camillo Hospital
Kazakhstan Astana, National Research Cardiac Surgery Center
Netherlands Rotterdam, Erasmus MC
Switzerland Bern, Inselspital
Zurich, Kinderspital
Turkey Izmir, Ege University Hospital
Table 3: Demographic profile of 741 VAD patients
Characteristics n
Mean age (median, range), years 53.3 (56, 0–83)
Gender (male/female) 610/131
Race
African-American 2
Asian 65
Caucasian 672
Hawaiian/Pacific 1
Others 1
Aetiology of end-stage heart failure
Idiopathic dilated cardiomyopathy 348
Ischaemic cardiomyopathy 294
Restrictive cardiomyopathy 8
Hypertrophic obstructive cardiomyopathy 2
Toxin-induced cardiomyopathy 13
Post-partal cardiomyopathy 5
Myocarditis 38
End-stage valvular heart disease 15
Congenital heart disease 13
Neoplasia 5
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implantation, and 8 patients received a third, 4 patients a fourth
and 2 patients a ﬁfth implantation, respectively.
Table 7 shows the indications for VAD implantation (n = 825) in
741 patients. VADs were implanted mostly to possible bridge
patients to transplant (n = 312, 37.8%) or bridge to transplantation
(n = 202, 24.5%). VAD as destination or permanent therapy was
implanted in 130 (15.8%) patients.
INTERMACS LEVELS
The EUROMACS database shows that VAD implantation was per-
formed mostly in patients on INTERMACS levels 2 and 3, as shown
in ref. [5] Table 8.
OUTCOME OF VAD IMPLANTATION
Types of ventricular assist device implanted
Figure 2 shows the types of VADs implanted on both paediatric
and adult patients from 1 January 2011 to 31 December 2013,
entered into the EUROMACS database.
Survival
The overall actuarial survival of 650 adult patients (aged ≥17 years)
with LVAD and BiVAD at a mean follow-up of 264.6 (median: 180,
range: 0–1363) days, is 88.7, 68.4, 59.1 and 57.3% at 30 days, 1, 2
and 3 years, respectively (Fig. 3).
Stratiﬁed according to site of VAD implantation, the actuarial
survival rate of 583 adult patients with a continuous ﬂow LVAD
implanted either as destination therapy or bridge to transplant is
92.2, 72.5, 62.8 and 60.9%, at 30 days, 1, 2 and 3 years, respectively
(Fig. 4). In comparison with a similar cohort in INTERMACS, the 1-
and 3-year actuarial survival rate is 80 and 59%, respectively [6].
The actuarial survival rate of 67 patients with BiVAD (mostly pul-
satile extracorporeal systems) is 52.5, 26.4 and 17.6% at 30 days, 1
and 2 years, respectively (Fig. 4).
Figure 5 shows the age group-based actuarial survival of
patients with primary LVAD and BiVAD support. At 3 years, the ac-
tuarial survival is 79, 56, 40 and 39% in patients <50, 50–64, 65–70
and >70 years of age, respectively.
The major adverse events (Table 9), which can be found in pro-
blems with the device, malfunctions, such as loosening, wear or
breaking of the drive line and pump thrombosis, were reported in
87 (20.1%) of the cases. As other groups have reported [7], patients
with continuous ﬂow assist devices have a higher risk for major
bleeding. In the EUROMACS database, major bleeding (requesting
at least one unit of blood transfusion) was reported 113 times
(26.1%), whereas 153 (35.3%) major infections (to be deﬁned),
caused by the drive line, which is an entry port for bacteria, were
observed. Neurological dysfunction (stroke) occurred in 71
(16.4%) of the adverse events, whereas 9 (2.1%) of the adverse
events were a combination of one or more.
The reasons for decease, and of multiorgan failure, in patients
receiving MCS is that the progress of end-stage cardiac disease,
expressed in INTERMACS levels, is in most instances on level 1
through 3 (607 patients, 70.1%).
In Table 10, the causes of death of 293 VAD patients are broken
down. A total of 89 (30.4%) died of MOF, 69 (23.5%) of infection or
Table 4: Patient characteristics according to gender and
blood groups
Blood group Male Female Total Percentage
A 277 48 325 43.9
B 75 20 95 12.8
AB 36 13 49 6.6
0 221 50 271 36.6
Unspecified 1 0 1 0.1
Total 610 131 741
Percentage 82.3 17.7
Table 5: Types of VADs implanted stratified according to age
Implant and type of flow Age at implant/years
<17 17–65 >65 Unspecified All
LVAD alone
Continuous 6 497 88 1 592
Pulsatile 4 6 0 3 13
Unspecified 0 6 2 0 8
LVAD + RVAD
Continuous 0 37 4 0 41
Continuous LVAD and pulsatile RVAD 0 1 0 0 1
Continuous LVAD and unspecified RVAD 0 1 0 0 1
BiVAD alone
Continuous 0 16 2 0 18
Continuous LVAD and pulsatile RVAD 0 1 0 0 1
Continuous LVAD and unspecified RVAD 0 4 1 0 5
Pulsatile LVAD and continuous RVAD 0 1 0 0 1
Pulsatile 5 16 1 4 26
Pulsatile LVAD and unspecified RVAD 0 0 0 1 1
Unspecified LVAD and unspecified RVAD 0 4 0 1 5
All implants 15 590 98 10 713
VAD: ventricular assist device; RVAD: right ventricular assist device; LVAD: left ventricular assist device; BiVAD: biventricular assist device.
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sepsis, 37 (12.6%) of cardiopulmonary failure, 20 (6.8%) of
cerebro-vascular accidents, 18 (6.1%) of a major bleeding and 60
(20.5%%) of other causes. Other causes are cancer: 2, suicide 2,
technical problems 1 and unknown 55.
Adverse events
Based on the EUROMACS database, 433 major adverse events
included VAD malfunction (i.e. pump thrombosis, driveline breaks,
cable wear and pump stops) bleeding, infection and stroke
(Table 9). The 3-year freedom from VAD malfunction was 85.2%,
while freedom from bleeding, infection and stroke were 89, 82
and 93.5%, respectively (Fig. 6).
COMMENTS
True to its objectives, the EUROMACS database, the ﬁrst European-
based MCS registry, has evolved into becoming an important
database, for improvements in VAD-patient care and research. The
EUROMACS database shows that 59% of patients with MCS were in
INTERMACS levels 2 and 3, whereas the ﬁfth INTERMACS report
showed a total of 62.9% of patients on these two levels [6].
Likewise, in comparison with the ﬁfth INTERMACS report,
wherein 19.7% of patients were in critical cardiogenic shock at the
time of implantation, the EUROMACS database showed only
12.1% of patients in this category.
In the ﬁrst 19 months of its establishment, the EUROMACS
registry has evolved into an EACTS-database in which European
hospitals and those from other member countries can upload
their MCS patient data. The accumulated data of 825 implanted
MCS devices could now be analysed, and compared with inter-
national data from registries in other parts of the world.
The strengths of the EUROMACS registry are the quality manage-
ment, the afﬁliation with the EACTS as an ofﬁcial committee, as well
Table 7: Indications for VAD implantation
Purpose of implantation n %
Rescue 46 5.6
Bridge to recovery 7 0.8
Possible bridge to transplant 312 37.8
Bridge to transplant, on waiting list 202 24.5
Destination therapy 130 15.8
Other 128 15.5
Total 825 100.0
Table 8: INTERMACS levels of 825 VAD implantations in
741 patients
INTERMACS level n %
Critical cardiogenic shock 100 12.1
Progressive decline 251 30.4
Stable but inotrope dependent 236 28.6
Resting symptoms 102 12.4
Exertion intolerant 22 2.7
Exertion limited 2 0.2
Advanced NYHA class 3 3 0.4
Unspecified 109 13.2
Total (%) 825 100.0
NYHA: New York Heart Association.
Table 6: Number of implantations of mechanical circulatory support (MCS) according to type of VADs
Operation sequence Percentage
1 2 3 4 5 All
LVAD alone
No secundary device 608 26 1 1 0 636 77.10
LVAD + RVAD
Long-term device 1 0 0 0 0 1 0.10
Short-term device 45 0 0 0 0 45 5.50
Other 2 0 0 0 0 2 0.20
Total 48 0 0 0 0 48
RVAD alone
No secundary device 8 0 2 0 0 10 1.20
With short-term device 2 34 2 2 1 41 5.00
Other 0 0 1 0 0 1 0.10
None recorded 0 1 0 0 0 1 0.10
Total 10 35 5 2 1 53
BiVAD alone
No secundary device 34 0 0 0 0 34 4.10
Short-term device 9 0 0 0 0 9 1.10
Other 7 0 0 0 0 7 0.80
None recorded 7 1 0 0 0 8 1.00
Total 57 1 0 0 0 58
TAH 7 1 0 0 1 9 1.20
Unspecified 11 7 2 1 0 21 2.50
All 741 70 8 4 2 825 100.00
Percentage 90% 8.4% 1% 0.40% 0.20% 100%
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as the fact that the registry overcomes multiple languages and cultural
differences and its ability to function as an industry-independent
post-market surveillance system. In addition, the EUROMACS actively
supervises the registry itself, and has taken the initiative to com-
mence the auditing of individual centres, instead of the respective
government agencies.
Our goal is for the database to assume a stature and quality,
which other agencies can compare with, make use of and respect.
We would like to see this database to be utilized more for scientif-
ic research; hence, we encourage clinicians to submit research
proposals with general and speciﬁc objectives to answer relevant
issues and concerns.
Presently, EUROMACS prepares to share data with IMACS,
which is an ISHLT subsidiary. Whereas INTERMACS receives data
from US hospitals, IMACS implemented all INTERMACS data and
strives to combine data from several regional registries such as
from Japan, South-East Asia and Australia. The cooperation of
Figure 3: Overall survival of primary LVD and BiVAD implantations in adults;
continuous ﬂow LVAD: actuarial survival with 95% conﬁdence intervals (n = 583
LVADs and n = 67 BiVADs). LVAD: left ventricular assist device; BiVADs: biventri-
cular assist devices.
Figure 2: Types of VAD implanted from 1 January 2011 to 31 December 2013. VAD: ventricular assist device.
Figure 5: Age group-based actuarial survival of adult patients with primary
LVAD and BiVAD support; continuous ﬂow LVAD; age at implantation.
Figure 4: Actuarial survival of 650 adult primary implant patients stratiﬁed
according to the type of VAD; continuous ﬂow LVAD: actuarial survival and
implant type with 95% conﬁdence intervals.
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EUROMACS with IMACS has been decided upon recently by
sharing compressed data sets.
EUROMACS is now a well-established instrument of increasing
importance for its members, giving them insights into their own
results as well as the possibility to compare these results with
outcomes of other clinical groups. With MCS being an estab-
lished treatment for patients with end-stage heart failure, the
collection of a carefully collected, high-quality and valid data is
essential to document the efﬁcacy, long-term durability and
impact on the quality of life of patients who underwent MCS im-
plantation. EUROMACS database is necessary to yield reliable
scientiﬁc data; thus, it allows for continuing improvement in the
quality of patient care.
SUPPLEMENTARYMATERIAL
Supplementary material is available at EJCTS online.
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to search for the presentation on the EACTS library
Dr T. Bottio (Padova, Italy): I would ﬁrstly like to congratulate for the initiative of
creating the European database and the progress made so far. I consider it a
project with excellent perspectives given the continuing interest in the ﬁeld of
mechanical circulatory support during the recent years. Additionally, consider-
ing the progress not only in the device technology but also in the surgical tech-
niques, a continuous approachable comparison of single centre results with
the data collected in similar centres promotes meaningful scientiﬁc research. I
have four simple technical questions for you.
What are the criteria to be fulﬁlled for a centre to become a member of the
EUROMACS registry? Is it a membership on invitation from the EUROMACS as-
sociation or on the request of the different centres?
Table 10: Causes of death
Causes of death n %
Infection and sepsis 69 23.5
Cerebro-vascular 20 6.8
Cardiopulmonary 37 12.6
Multiorgan failure 89 30.4
Bleeding 18 6.1
Other 60 20.5
Total 293 100
Figure 6: Three-year freedom from major adverse events with 95% conﬁdence
intervals; (n = 525 LVADs and n = 64 BiVADs); continuous ﬂow primary LVAD and
BiVAD implantations for adults.
Table 9: Major adverse events
Major adverse events n %
Device malfunction 87 20.1
Major bleeding 113 26.1
Major infection 153 35.3
Neurological dysfunction 71 16.4
combination 9 2.1
Total 433 100.0
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Mr de By: Any surgeon can become a member of EUROMACS and any
centre can, of course, start contributing the data. The only criterion is that you
sign a quite simple agreement with the association. The agreement states, on
the one hand, that we will keep your data safe and that we are punishable if we
wouldn’t do that, and of course we have safeguards. Our data are behind secure
protection, ﬁrewalls. Second, as a centre, you promise that you will provide
your data on a regular basis, not one year or two years after the date, and that
you will include all the patients and not leave out any of the cases. This is a
simple agreement, and if it has been signed, you can start entering your data.
Dr Bottio: Are the input data subjected to modiﬁcation or enlargement? If
yes, on what basis is a new parameter considered suitable to be collected for
the registry?
Mr de By: I am not sure if I understood your question correctly.
Dr Bottio: The data that is entered in the database can be changed over
time?
Mr de By: Yes, of course. There is a board consisting of colleagues, cardiolo-
gists and cardiac surgeons. If the question comes up, should we add a new data
ﬁeld, yes or no, because of scientiﬁc developments or because of innovation,
then this question will be answered. If the committee is not sure, then we have
a scientiﬁc advisory committee which could advise us to do so or not.
Dr Bottio: Are part of the inserted data also the surgical access, the management
of the anaesthesiology, and the management of anticoagulation arrangement?
Mr de By: Anaesthesiology no; anticoagulation, yes.
Dr Bottio: And type of access?
Mr de By: Type of?
Dr Bottio: Surgical access, surgical approach.
Mr de By: Not yet, no.
Dr Bottio: To obtain access to the registry data, the centre must be a
member?
Mr de By: It is only logic that you become a member. There are no ﬁnancial
requirements. Well, technically it is possible not to be a member and to
provide data. Yes, it is.
Dr M. Siepe (Freiburg, Germany): From what you saw in the EUROMACS data
so far, is there a major difference as compared to the INTERMACS patient’s
proﬁle or to the outcome? What was your ﬁrst impression?
Mr de By: Of course, we started EUROMACS because there is a difference
between Europe and the United States. In Europe all CE mark devices are
allowed on the market and can be entered into the EUROMACS database.
In the United States, only FDA-approved devices can be entered into a regis-
try such as INTERMACS. We recently submitted our annual report showing
more analyses than I could show today, and we did not see, I cannot use the
word signiﬁcant because we could not have a direct comparison, but we did
not see any large difference between United States outcomes and European
outcomes.
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